Poor 2-Year Overall Survival Observed Following HSCT in TP53-Mutant AML

News
Article

Patients with TP53-mutant acute myeloid leukemia experienced poor overall survival following treatment with hematopoietic stem cell transplantation, suggesting a need for more careful patient selection, further clinical trial enrollment, and personalized treatment strategies.

Treatment with hematopoietic stem cell transplantation yielded poor overall survival (OS) in patients with TP53-mutant acute myeloid leukemia (AML), highlighting the need for more sophisticated patient selection, further enrollment on clinical trials, and more personalized treatment approaches, according to findings from a poster presented at the 2022 Tandem Meeting.

At a median follow up of 2 years in 5 studies, the OS rate was 15.3% (95% CI, 0.05-0.28; I2 = 88%) among patients with TP53-mutant AML (n = 451). The pooled 2-year OS rate was 17.2% (95% CI, 0.05-0.34; i2 = 93%) in 3 studies (n = 404). Moreover, the pooled 2-year progression-free survival rate was 12% (95% CI, 0.02-0.34; I2 = 94%; n = 241). Investigators also reported a pooled relapse rate of 79.1% (95% CI, 0.57-0.95; I2 = 90%; n = 258) with a median of 2 years of follow up and a pooled 2-year relapse rate of 85.7% (95% CI, 0.55-1.0; I2 = 94%; n = 209). A single study reported on nonrelapse mortality, with a 3-year rate of 32.5%.

“Novel therapeutic strategies based on disease biology are needed in prospective, exploratory clinical trials in both transplant and non-transplant settings,” the investigators wrote.

Investigators noted that TP53 mutations are associated with a poor prognosis and resistance to chemotherapy across numerous hematologic malignancies. As the mutation has been identified in up to 20% of patients with AML and is typically reported alongside a 2-year OS rate of 10%, investigators conducted the systemic review and meta-analysis to assess outcomes with HSCT in this population.

A total of 6 out of 387 screened studies were included in the analysis. The review included a total of 460 patients with TP53-mutant AML. The median patient age was 55 years (range, 19-90). The median follow-up time for all studies was 52.5 months (range, 0.9-407.3).

Reference

Shahzad M, Chaudhary SG, Tariq E, et al. Outcomes with allogenic hematopoietic stem cell transplantation in TP53-mutated acute myeloid leukemia: a systematic review and meta-analysis. Presented at: 2022 Tandem Meeting; April 23-26, 2022; Salt Lake City, UT. Abstract 146.

Recent Videos
Both clinicians and patients should have as much information as possible to participate in shared decision-making for CLL care, says Jacob D. Soumerai, MD.
Sequencing different treatments in the first 3 lines of therapy represents a challenge in chronic lymphocytic leukemia, according to Deborah Stephens, DO.
Compared with second-generation tyrosine kinase inhibitors, asciminib was better tolerated in patients with chronic myeloid leukemia.
Bulkiness of disease did not appear to impact PFS outcomes with ibrutinib plus venetoclax in the phase 2 CAPTIVATE study.
A panel of 3 experts on CML
A panel of 3 experts on CML
A panel of 3 experts on CML
A panel of 3 experts on CML
A panel of 3 experts on CML
A panel of 3 experts on CML